SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M. Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology, a prospective study. J Rheumatol 1991; 18: 154251.
  • 2
    Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 235964.
  • 3
    Ramos M, De Castro JA. HLA-B27 and the pathogenesis of spondyloarthritis. Tissue Antigens 2002; 60: 191205.
  • 4
    Maksymowych WP. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol 2000; 27: 2295301.
  • 5
    Gratacos J, Collado A, Pons F, Osaba M, Sanmarti R, Roque M, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 1999; 42: 231924.
  • 6
    Cooper C, Carbone L, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 1994; 21: 187782.
  • 7
    Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38: 61827.
  • 8
    Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a department of veterans affairs cooperative study. Arthritis Rheum 1996; 39: 200412.
  • 9
    Maksymowych WP. Bisphosphonates–anti-inflammatory properties. Curr Med Chem 2002: 1; 1528.
  • 10
    Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499505.
  • 11
    Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, Lopez de Castro JA. Molecular mimicry of an HLA–B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002; 277: 3757381.
  • 12
    Wildner G, Diedrichs-Mohring M, Thurau SR. Induction of arthritis and uveitis in Lewis rats by antigenic mimicry of peptides from HLA–B27 and cytokeratin. Eur J Immunol 2002; 32: 299306.
  • 13
    Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis Arthritis Rheum 2002; 46: 76673.
  • 14
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 118793.
  • 15
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 134652.
  • 16
    Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondylarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 42833.
  • 17
    Brandt J, Haibel H, Sieper J, Reddig, J, Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 2001; 44: 29367.
  • 18
    Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29: 95965.
  • 19
    Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 134956.